- $394.69bn
- $457.81bn
- $56.33bn
- 97
- 42
- 85
- 88
Annual balance sheet for Abbvie, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 8,479 | 9,830 | 9,229 | 12,816 | 5,555 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 8,822 | 9,977 | 11,254 | 11,155 | 10,919 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 24,173 | 27,928 | 28,463 | 33,002 | 25,582 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 6,143 | 5,872 | 5,672 | 5,733 | 5,857 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 150,565 | 146,529 | 138,805 | 134,711 | 135,161 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 28,661 | 35,194 | 29,538 | 37,841 | 38,749 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 137,489 | 131,121 | 121,551 | 124,351 | 131,836 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 13,076 | 15,408 | 17,254 | 10,360 | 3,325 |
| Total Liabilities & Shareholders' Equity | 150,565 | 146,529 | 138,805 | 134,711 | 135,161 |
| Total Common Shares Outstanding |